Inquirer News

FDA grants emergency use authorization to J&J COVID-19 vaccine

APPROVED FOR TESTING Janssen’s candidate vaccine leverages its AdVac platform, which was also used to develop and manufacture an Ebola vaccine regimen, and construct its Zika, RSV and HIV investigational candidate vaccines. —REUTERS

FDA grants emergency use authorization to J&J COVID-19 vaccine

MANILA, Philippines — Johnson & Johnson has secured an emergency use authorization (EUA) for its Janssen COVID-19 vaccine from the Food and Drug Administration (FDA), Secretary Carlito Galvez Jr., the country’s vaccine manager, said Monday.

“Regarding Johnson & Johnson, we thank the FDA because its EUA has been released. Now, we have five vaccines with an EUA,” Galvez said in Filipino during a pre-recorded meeting of President Rodrigo Duterte with his Cabinet.

“The only ones left [with an EUA] are Moderna at Novovax,” he added.

The four other vaccines that have secured an EUA are those developed by Sinovac BioTech, AstraZeneca, Pfizer-BioNTech, and Russia’s Gamaleya Institute.

The Philippines has already reserved six million doses of J&J’s single-shot vaccine, Philippine Ambassador to the United States Jose Romualdez previously said.

J&J’s vaccine is said to be 85.4 percent effective in preventing the severe respiratory disease.

RELATED STORY:

What you need to know about the Johnson & Johnson vaccine

[atm]
Exit mobile version